Photo Credit: Richard Villalon
Regardless of Anticoagulation Use, Patients with cancer are at High Risk for Clinically Relevant Bleeding (CRB), According to Study In Blood. Cihan Ay, MDand Colleagues Investigated Bleeding Event Prognosis In 791 Patients with cancer who Initiated Systemic Anticancer Therapies in the Vienna Cancer, Thrombosis, and Bleeding Study: 48% Female, Median Age 63 Years, with various cancer Types (65.5% with stage iv). OVER A MEDIAN 19-MONTH FOLLOW-UP, THERE OBSERED 194 CRB Events in 139 PATS: 30.0% TUMOR-REASC, 46.0% GASTROINTINAL, AND 5.0% INTROCES. FIRST, CRB and Major Bleeding 12-MONTH CUMULATIVE INCIDENCE WAS 16.6% and 9.1%, respective, in the WHOLE cohort and 14.4% and 7.0%, respective, in thhose without anticoagulation. Lower Baseline Hemoglobin and Albumin Were Associated with Bleeding in Patients Without Anticoagulation. Seven Bleeding Events Were Fatal, of Which Six Occred in Patients Without Anticoagulation. “In Patients with Cancer, Bleeding Events Representation A Frequent Complication and Are Associated with Increeded Mortality,” The Study Authors Stated.
